

## Special Issue

# Checkpoint Markers and Cancer Microenvironment: What Do We Know?

### Message from the Guest Editor

Inhibitory checkpoint molecules are targets for cancer immunotherapy due to their potential for use in multiple types of cancer. Immune checkpoint blockade has vastly changed the landscape of cancer treatment and has shown a promising prognosis for cancer patients. However, the majority of patients will not benefit from immune checkpoint inhibitor therapy (innate resistance), and a substantial proportion of the responding patients will progress while on treatment (acquired resistance). Therefore, it is essential to investigate biomarkers to predict the efficacy of immune checkpoint inhibitors. In this Special Issue, we hope to collect papers on checkpoint markers for different cancers. We hope that this will promote study in this field.

---

### Guest Editor

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport, Victoria University, Melbourne, VIC 3011, Australia

---

### Deadline for manuscript submissions

closed (31 March 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/si/126480](https://mdpi.com/si/126480)

*Cancers*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.5  
CiteScore 8.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)